WO2023102512 - PREDICTION OF SEVERITY OF COVID-19 AND METHODS OF TREATMENT
National phase entry:
Publication Number
WO/2023/102512
Publication Date
08.06.2023
International Application No.
PCT/US2022/080795
International Filing Date
02.12.2022
Title **
[English]
PREDICTION OF SEVERITY OF COVID-19 AND METHODS OF TREATMENT
[French]
PRÉDICTION DE LA GRAVITÉ DE COVID-19 ET PROCÉDÉS DE TRAITEMENT
Applicants **
VANDA PHARMACEUTICALS INC.
Inventors
SMIESZEK, Sandra
POLYMEROPOULOS, Vasilios
POLYMEROPOULOS, Christos
PRZYCHODZEN, Bartlomiej
POLYMEROPOULOS, Mihael
Priority Data
63/264,896
03.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2056 | |
| EPO | Filing, Examination, Granting | 8735 | |
| Japan | Filing, Examination, Granting | 2230 | |
| South Korea | Filing, Examination, Granting | 2066 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
20,427
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates generally to coronavirus disease 2019 (COVID-19) and more particularly to the prediction of severity of COVID-19 manifestation in a patient or in an individual at risk of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on a level of chemokine (C-X-C motif) ligand 16 (CXCL16) expression in and/or the rs10490770 genotype of the patient or individual.[French]
L'invention concerne de manière générale la maladie de coronavirus 2019 (COVID-19) et plus particulièrement la prédiction de la gravité de la manifestation de COVID-19 chez un patient ou chez un individu présentant un risque d'infection par le coronavirus du syndrome respiratoire aigu sévère 2 (SARS-CoV-2) sur la base d'un niveau d'expression du ligand 16 de chimiokine (motif C-X-C) (CXCL16) et/ou du génotype rs10490770 du patient ou de l'individu.